{"preliminary_commentary":{"by_channel":{"x_thread":73,"podcast":21,"youtube":19},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04158440\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"NEOTORCH","nct_id":"NCT04158440","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neotorch-nct04158440. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Toripalimab","label":"4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg)","type":"EXPERIMENTAL"},{"description":"Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Placebo","label":"4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-07-03","type":"ACTUAL"},"conditions":["Stage II-III Non-small Cell Lung Cancer"],"enrollment":{"count":501,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab","otherNames":["Cisplatin;","Carboplatin;","Pemetrexed;","Paclitaxel;","Docetaxel"],"type":"DRUG"},{"name":"4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )","otherNames":["Cisplatin;","Carboplatin;","Pemetrexed;","Paclitaxel;","Docetaxel"],"type":"DRUG"}],"last_update":"2026-07-23","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","official_title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"MPR rate in stage III population evaluated by BIPR","timeFrame":"up to 7 weeks after neoadjuvant"},{"measure":"EFS in stage III population evaluated by investigators","timeFrame":"up to 3 years"},{"measure":"MPR rate in stage II-III population evaluated by BIPR","timeFrame":"up to 7 weeks after neoadjuvant"},{"measure":"EFS in stage II-III population evaluated by investigators","timeFrame":"up to 3 years"}],"references":[{"citation":"Fang W, Wang Y, Wang W, Wu L, Sun L, Zhang P, Lu S; Neotorch Investigators; Zheng Y, Chen Q, Tan L, Yang L, Mei J, Sun X, Xu S, Shan J, Yang N, Yu D, Chen Y, Yu G, Hu X, Xing L, Wu N, Chen K, Tian H, Zhang X, Liu Y, Zhou M, Fang H, Li S, Ye M, Wu G, Cao L, Jiang J, Zhu K, Kang M, Xu H, Li X, Zhu L, Zhong A, Sun Q, Wang C, Ma H, Cai K, Zhang Y, Zhang X, Hu H, Chen J, Yang Z, Hang X, Zhang W, Huang Y, Hu J, Zhang L, Yao J, Zhang Z, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Xu J, Cao D, Zou J. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial. JAMA Surg. 2026 Jul 15:e262711. doi: 10.1001/jamasurg.2026.2711. Online ahead of print.","pmid":"42455561","type":"DERIVED"},{"citation":"Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li S, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.","pmid":"38227033","type":"DERIVED"}],"start_date":{"date":"2020-04-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","url":"https://clinicaltrials.gov/study/NCT04158440"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neotorch-nct04158440"}